Posted by Michael Wonder on 11 May 2023
Otsuka and Lundbeck announce US FDA approval of supplemental new drug application for Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s disease
10 May 2023 - Rexulti is the first and only pharmacological treatment approved in the US for agitation associated with dementia due to Alzheimer’s disease.
Otsuka and Lundbeck announce the US FDA has approved the supplemental new drug application of Rexulti (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer’s disease.
